73
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Clinical blockade of PD1 and LAG3--potential mechanisms of action.

      1 , 1
      Nature reviews. Immunology

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dysfunctional T cells can render the immune system unable to eliminate infections and cancer. Therapeutic targeting of the surface receptors that inhibit T cell function has begun to show remarkable success in clinical trials. In this Review, we discuss the potential mechanisms of action of the clinical agents that target two of these receptors, programmed cell death protein 1 (PD1) and lymphocyte activation gene 3 protein (LAG3). We also suggest correlative studies that may define the predominant mechanisms of action and identify predictive biomarkers.

          Related collections

          Author and article information

          Journal
          Nat. Rev. Immunol.
          Nature reviews. Immunology
          1474-1741
          1474-1733
          Jan 2015
          : 15
          : 1
          Affiliations
          [1 ] Immune Therapy Program, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, Ontario, M5G 2M9, Canada.
          Article
          nri3790
          10.1038/nri3790
          25534622
          43447aa0-4fdc-4940-a806-fa7608fcfb4b
          History

          Comments

          Comment on this article